Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  AC Immune SA    ACIU   CH0329023102

AC IMMUNE SA (ACIU)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/11/2018 01/12/2018 01/16/2018 01/17/2018 01/18/2018 Date
13.27(c) 13.48(c) 13.05(c) 13.18(c) 13.1 Last
45 436 74 055 41 336 54 466 18 799 Volume
+1.30% +1.58% -3.19% +1.00% -0.61% Change
More quotes
Financials ($)
Sales 2017 17,8 M
EBIT 2017 -26,7 M
Net income 2017 -30,7 M
Finance 2017 118 M
Yield 2017 -
Sales 2018 25,1 M
EBIT 2018 -39,0 M
Net income 2018 -41,4 M
Finance 2018 81,1 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 35,1x
EV / Sales2018 26,4x
Capitalization 744 M
More Financials
Company
AC Immune SA is a clinical stage biopharmaceutical company, which engages in leveraging two proprietary technology platforms to discover, design and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding.It's... 
More about the company
Surperformance© ratings of AC Immune SA
Trading Rating : Investor Rating :
More Ratings
Latest news on AC IMMUNE SA
2017 AC Immune Shares Insights from Key Opinion Leader Meeting on Tau as a Therape..
2017 AC Immune to Host Key Opinion Leader Meeting on Tau as a Therapeutic and Diag..
2017 AC Immune SA to Receive Milestone Payment for Anti-Tau Antibody Moving into P..
2017 AC Immune to Present at Two Investor Conferences and Provide Scientific Updat..
2017 AC Immune Awarded Continuation of 2015 Grant from The Michael J. Fox Foundati..
2017 Ac immune completes recruitment for low-dose cohort in world's first clinica..
2017 AC IMMUNE : Discovers next-generation antibodies focused on neurodegenerative di..
2017 Ac immune reports second quarter 2017 financial results
2017 Ac immune provides seven updates on its pipeline and technology at the alzhei..
2017 Ac immune announces results of annual general meeting
More news
Sector news : Biotechnology & Medical Research - NEC
01/17 CELGENE : Conducts Deal Talks With Juno -- WSJ
01/16 CELGENE : in Talks to Buy Juno Therapeutics -- Update
01/16 CELGENE : in Talks to Buy Juno Therapeutics
01/12 Drugmakers see a pricing blueprint in an $850,000 gene therapy
01/12 SPARK'S PRICE FOR LUXTURNA BLINDNESS : Icer
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
01/16Get the latest ratings for $INOV $REIS $KAR $VRTV $ACIU in your inbox with Ma.. 
01/09Contrasting AC Immune $ACIU & The Competition  
2017AC Immune $ACIU Upgraded by BidaskClub to Strong-Buy  
2017UPSIDE MOMENTUM ALERT: $ACIU AC IMMUNE SA COMMON ? TradeIdeas via  
2017TREND REVERSAL DOWN ALERT: $ACIU AC IMMUNE SA COMMON ? TradeIdeas via  
More tweets
Qtime:61
News from SeekingAlpha
2017 Forensic Analysis Value Stock Selections - December
2017 AC Immune (ACIU) Presents At Jefferies 2017 London Healthcare Conference - Sl..
2017 AC Immune misses by $0.03
2017 AC Immune discovers two new antibodies targeted to neurodegenerative diseases..
2017 Now Is The Perfect Time To Diversify Internationally
Chart AC IMMUNE SA
Duration : Period :
AC Immune SA Technical Analysis Chart | ACIU | CH0329023102 | 4-Traders
Technical analysis trends AC IMMUNE SA
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 21,7 $
Spread / Average Target 64%
EPS Revisions
Managers
NameTitle
Andrea Pfeifer CEO, Director & Head-Investor Relations
Martin Velasco Chairman
Jörg Hornstein Chief Financial Officer
Andreas Muhs Chief Scientific Officer
Detlev H. Riesner Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
AC IMMUNE SA1.95%744
CELLTRION, INC.--.--%40 725
IQVIA HOLDINGS INC2.07%20 784
LONZA GROUP2.47%20 682
INCYTE CORPORATION-3.23%19 342
ALNYLAM PHARMACEUTICALS, INC.-1.90%12 256